Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

1.840 -0.070 (-3.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,129
Open 1.900
Bid (Size) 1.800 (1)
Ask (Size) 1.910 (1)
Prev. Close 1.910
Today's Range 1.750 - 1.905
52wk Range 1.325 - 3.160
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga

Performance

YTD
-10.7%
-10.7%
1 Month
-12.8%
-12.8%
3 Month
+0.5%
+0.5%
6 Month
+21.1%
+21.1%
1 Year
-16.7%
-16.7%

More News

Read More
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
From Adagene Inc.
Via GlobeNewswire
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic
Via Stocktwits
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
From Adagene Inc.
Via GlobeNewswire
Adagene to Participate in Two Investor Conferences in September
From Adagene Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
From Adagene Inc.
Via GlobeNewswire
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
From Adagene Inc.
Via GlobeNewswire
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
Adagene announces up to $25 million strategic investment from Sanofi
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Jefferies Global Healthcare Conference 2025
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
From Adagene Inc.
Via GlobeNewswire
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Leerink’s Global Healthcare Conference 2025
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
From Adagene Inc.
Via GlobeNewswire
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
From Adagene Inc.
Via GlobeNewswire
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
From Adagene Inc.
Via GlobeNewswire
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at
From Adagene Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Adagene Inc. - ADS, each representing 1.25 ordinary shares publicly traded?
Yes, Adagene Inc. - ADS, each representing 1.25 ordinary shares is publicly traded.
What exchange does Adagene Inc. - ADS, each representing 1.25 ordinary shares trade on?
Adagene Inc. - ADS, each representing 1.25 ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares is ADAG on the Nasdaq Stock Market
What is the current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares is 1.840
When was Adagene Inc. - ADS, each representing 1.25 ordinary shares last traded?
The last trade of Adagene Inc. - ADS, each representing 1.25 ordinary shares was at 10/14/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.